


## SUPPLEMENTARY MATERIALS

Reagent	Color	Clone	Company	Isotype
Live/Dead Fixable Aqua Stain	AmCyan		Thermo Fisher	
CD3	BV650	UCHT1	BD	IgG1 Mouse, K
CD56	ECD	N901	IOtest (BC)	IgG1 Mouse, K
NKG2C	APC/FITC	REA205	Miltenyi	REA
NKG2A	PeCy7	Z199	IOtest (BC)	IgG2b Mouse, K
KIR2DL1/S1	PeCy5.5	EB6B	IOtest (BC)	IgG1 Mouse, K
KIR2DL2/L3/S2	BV605	CH-L	BD	IgG2b Mouse, K
KIR3DL1	BV711	DX9	BD	IgG1 Mouse, K
KIR3DL1/S1	APCVio770	REA168	Miltenyi	REA
CD107a	BV786	H4A3	BD	IgG1 Mouse, K
IFN- $\gamma$	AF700	B27	BD	IgG1 Mouse, K
CD94	APC	NA	Miltenyi	REA
TCRgd	PE	B1	Biologend	IgG1 Mouse, K
Vd1	APCVio770	REA173	Miltenyi	REA
Vd2	PerCP-Vio 700	REA771	Miltenyi	REA
CD4	Alexa 700	SK3	Biologend	IgG1 Mouse, K
CD8	BV570	RPA-T8	Biologend	IgG1 Mouse, K
CD16	BV786/BV421	3G8	Biologend	IgG1 Mouse, K
Fc $\epsilon$ R1 $\gamma$	FITC	NA	Millipore	IgG Rabbit
HLA-E	PE	3D12	Biologend	IgG1 Mouse, K
HLA-ABC	FITC	REA230	Miltenyi	REA
HLA-BC	FITC	REA672	Miltenyi	REA
HLA-C	PE	DT-9	BD	IgG2b Mouse, K


**Supplemental Table 1.** Antibodies used for phenotyping and functional analysis.

# Supplemental figure 1




**Supplemental Fig. 1. *NKG2A* non-coding SNPs discriminate *NKG2A* expression on CD8<sup>+</sup> T cells and Vδ2<sup>+</sup> T cells.** (A) *NKG2A* frequency and MFI of CD8<sup>+</sup> T cells grouped by selected *NKG2A* SNPs. (B) *NKG2A* frequency and MFI of Vδ2<sup>+</sup> T cells grouped by selected *NKG2A* SNPs. (C) *NKG2A* frequency and MFI of CD8<sup>+</sup> T cells stratified by *NKG2A* 440C/T genotype and HCMV serostatus. (D) Correlation between *NKG2A* MFI and *NKG2A*<sup>+</sup> frequency among CD8<sup>+</sup> T cells in HCMV<sup>-</sup> (blue), HCMV<sup>+</sup> (red) (E) *NKG2A* frequency and MFI of Vδ2<sup>+</sup> T cells stratified by *NKG2A* 440C/T genotype and HCMV serostatus. (F) Correlation between *NKG2A* MFI and *NKG2A*<sup>+</sup> frequency among Vδ2<sup>+</sup> T cells in HCMV<sup>-</sup> (blue), HCMV<sup>+</sup> (red). Mann-Whitney tests were performed and median ± IQRs presented panel A-C and E. Correlations were assessed using the Pearson correlation coefficient panel D and F. Symbols represent individual samples. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.

# Supplemental figure 2



**Supplemental Fig. 2. *CD94* polymorphism alone or combined with *NKG2A* polymorphism predicts *NKG2A* expression on  $CD8^+$  T cells and  $V\delta 2^+$  T cells.** (A)  $CD8^+$  T cell *NKG2A* frequency and MFI grouped by *CD94* polymorphism. (B)  $CD8^+$  T cell *NKG2A* frequency and MFI grouped by *CD94* and *NKG2A* polymorphism. (C)  $V\delta 2^+$  T cell *NKG2A* frequency and MFI grouped by *CD94* polymorphism. (D)  $V\delta 2^+$  T cell *NKG2A* frequency and MFI grouped by *CD94* and *NKG2A* polymorphism. (E) Correlation between *NKG2A*, *NKG2C* and *CD94* MFI on  $CD56^{dim}$  NK cells. (F) *NKG2A* and *CD94* MFI on subpopulations of  $CD56^{dim}$  NK cells, stratified by *CD94* SNPs in conjunction with *NKG2A* variants. (G) *CD94* MFI stratified by *CD94* SNPs in different  $CD56^{dim}$  NK cells population defined by *NKG2C* and *NKG2A* positivity. (H) *CD94* MFI on DN ( $NKG2A^-NKG2C^-$ ) NK cells cell stratified by *CD94* SNPs. Mann-Whitney tests were performed and median  $\pm$  IQRs presented panel A-D. Correlations were assessed using the Pearson correlation coefficient panel E. T-tests were performed and mean  $\pm$  SEM presented in panel G-H. Symbols represent individual samples. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$ .


## Supplemental figure 3



**Supplemental Fig. 3. *NKG2C* polymorphism predicts variable NKG2A expression on CD8<sup>+</sup> T cells and Vδ2<sup>+</sup> T cells.** (A) CD8<sup>+</sup> T cell NKG2A frequency and MFI grouped by *NKG2C* polymorphism. (B) CD8<sup>+</sup> T cell NKG2A frequency and MFI grouped by *NKG2C* polymorphism and HCMV serostatus. (C) Vδ2<sup>+</sup> T cell NKG2A frequency and MFI grouped by *NKG2C* polymorphism. (D) Vδ2<sup>+</sup> T cell NKG2A frequency and MFI grouped by *NKG2C* polymorphism and HCMV serostatus. (E) NKG2D MFI on CD56<sup>bright</sup> NK cells stratified by *NKG2D* SNPs. (F)


NKG2D MFI in different NK cell compartments (CD56<sup>dim</sup> NKG2A<sup>-</sup>, CD56<sup>dim</sup> NKG2A<sup>+</sup>, CD56<sup>bright</sup>) and correlation between NKG2A and NKG2D MFI. Mann-Whitney tests were performed and median  $\pm$  IQRs presented in panels A-D. T-tests were performed and mean  $\pm$  SEM presented in panel E. Correlations were assessed using the Pearson correlation coefficient in panel F. Symbols represent individual samples. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$ .

## Supplemental figure 4



**Supplemental Fig. 4. HLA-E expression or scoring methods do not predict NKG2A education on CD56<sup>dim</sup> NK cells.** PBMC from 400 different donors were cultured with K562 HLA-E KO target cells in a CD107a assay. (A) NKG2A<sup>asp</sup> degranulation frequency stratified by HLA-B leader peptide. (B) NKG2A<sup>asp</sup> degranulation frequency stratified by HLA-E alleles. (C) NKG2A<sup>asp</sup> degranulation frequency stratified by HLA-A Z-score. (D) NKG2A<sup>asp</sup> degranulation frequency stratified by Signal peptide SP-1C. (E) Correlation between HLA-E MFI and NKG2A<sup>asp</sup> degranulation frequency on PBMC of 100 donors cultured with 721.221 HLA-E KO target cells in a CD107a assay. Mann-Whitney tests were performed and median  $\pm$  IQRs presented in panels A, B and D. Correlations were assessed using the Pearson correlation coefficient in panels C and E. Symbols represent individual samples. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and \*\*\*\* $p < 0.0001$ .

# Supplemental figure 5





**Supplemental Fig. 5. HLA-C epitope is predictive of HLA-E expression and significantly associated with certain HLA-A and HLA-B alleles. (A) HLA-E MFI segregated by HLA-B leader peptide and HLA-E epitope. (B) HLA-E MFI grouped by HCMV serostatus. (C) Correlation**



between HLA-A expression level (by calculated Z-score) and HLA-E MFI or HLA-ABC MFI. (D) HLA-E MFI grouped by HLA-A alleles and ranked in croissant order. (E) Linkage disequilibrium between HLA-C epitope, HLA-B alleles, and HLA-A alleles. Positive and negative LD determined at a significance level of  $<0.05$ . (F) HLA-E and HLA-ABC MFI grouped by HLA-B alleles, coded by HLA-C epitope found to be in linkage disequilibrium with each allele and ranked in croissant order. HLA-B leader peptide noted in parentheses. T-tests were performed and mean  $\pm$  SEM presented in panels A and B. Correlations were assessed using the Pearson correlation coefficient in panel C. Linkage Disequilibrium were assessed using Chi-square test (E). Symbols represent individual samples.  $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ , and  $****p < 0.0001$ .

# Supplemental figure 6



**A**





**B**



**C**



**D**



**Supplemental Fig. 6. Impact HLA-B leader peptide and HLA-E alleles on NKG2A expression.** (A) NKG2A<sup>+</sup> NK cell frequency and NKG2A MFI stratified by HLA-B leader peptide and HCMV serostatus. (B) NKG2A<sup>+</sup> NK cell frequency and NKG2A MFI stratified by HLA-E alleles and HCMV serostatus. (C) NKG2A<sup>+</sup> NK frequency and MFI stratified by HLA-B leader peptide, *NKG2A* SNP genotype, and HCMV serostatus. (D) NKG2A<sup>+</sup> NK frequency and MFI stratified by HLA-E alleles, *NKG2A* SNP genotype, and HCMV serostatus. T-tests were performed and mean ± SEM are presented to analyze NKG2A frequencies (A-D). Mann-Whitney tests were performed and median ± IQRs are presented to analyze NKG2A MFI (A-D). Symbols represent individual samples. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001, and \*\*\*\**p* < 0.0001.